MorphoSys has partnered with Immatics Biotechnologies to develop novel antibody-based therapeutics against multiple proprietary cancer antigens differentiated by T cells.

Under the deal, MorphoSys will be provided access to several proprietary tumour-associated peptides (TUMAPs) discovered using Immatics’ Xpresident platform to develop novel antibody-based therapeutics against these targets in multiple solid and haematological cancers.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Xpresident provides access to novel antibody targets associated with proteins, which are present inside cancer cells.

"We are delighted to join forces with Immatics, a world leader in discovering truly novel cancer targets that would be otherwise inaccessible for antibody-based therapies."

Immatics will also receive MorphoSys’ Ylanthia antibodies against a number of its TUMAPs, with proprietary development rights.

MorphoSys chief scientific officer Dr Marlies Sproll said: "We are delighted to join forces with Immatics, a world leader in discovering truly novel cancer targets that would be otherwise inaccessible for antibody-based therapies."

See Also:

Both firms will pay each other milestones based on their respective development progress, in addition to royalties on marketed products.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Financial terms of the deal have not been disclosed.

Immatics Biotechnologies chief scientific officer Dr Harpreet Singh said: "The combination of MorphoSys’ outstanding capabilities to create antibodies and the unique access to intracellular targets through our Xpresident discovery engine provides both partners the opportunity to jointly deliver the next generation of transforming antibody drugs for cancer patients with high unmet medical need."

The therapeutic programmes currently being pursued by both firms aim to discover Ylanthia antibodies against the major histocompatibility complex (MHC) bound peptide targets to kill the tumour cells, according to Immatics.